157 related articles for article (PubMed ID: 22049975)
1. Interdisciplinary approach towards female patients with Fabry disease.
Weidemann F; Niemann M; Sommer C; Beer M; Breunig F; Wanner C
Eur J Clin Invest; 2012 Apr; 42(4):455-62. PubMed ID: 22049975
[TBL] [Abstract][Full Text] [Related]
2. Department-related tasks and organ-targeted therapy in Fabry disease: an interdisciplinary challenge.
Weidemann F; Sommer C; Duning T; Lanzl I; Möhrenschlager M; Naleschinski D; Arning K; Baron R; Niemann M; Breunig F; Schaefer R; Strotmann J; Wanner C
Am J Med; 2010 Jul; 123(7):658.e1-658.e10. PubMed ID: 20609689
[TBL] [Abstract][Full Text] [Related]
3. [Fabry disease].
Jakubowska E; Ryba M; Hruby Z
Przegl Lek; 2006; 63(4):218-9. PubMed ID: 17080745
[TBL] [Abstract][Full Text] [Related]
4. [Neurological complications of Fabry-disease].
Vastagh I; Constantin T; Kéri A; Rudas G; Fekete G; Bereczki D
Ideggyogy Sz; 2011 Jan; 64(1-2):29-35. PubMed ID: 21428036
[TBL] [Abstract][Full Text] [Related]
5. The Fabry cardiomyopathy: models for the cardiologist.
Weidemann F; Niemann M; Warnock DG; Ertl G; Wanner C
Annu Rev Med; 2011; 62():59-67. PubMed ID: 21090963
[TBL] [Abstract][Full Text] [Related]
6. [Division-related function and organ-related therapy in Fabry's disease. An interdisciplinary challenge].
Weidemann F; Sommer C; Duning T; Lanzl I; Möhrenschlager M; Naleschinski D; Baron R; Breunig F; Schaefer R; Strotmann J; Wanner C
Med Klin (Munich); 2009 Jan; 104(1):10-9. PubMed ID: 19142592
[TBL] [Abstract][Full Text] [Related]
7. [Biochemical and pathological studies on a carrier of Fabry's disease manifesting bouts of pain in the extremities].
Katayama M; Kobayashi T; Ohnishi A; Goto I; Kuroiwa Y
Rinsho Shinkeigaku; 1984 Jun; 24(6):575-80. PubMed ID: 6094070
[No Abstract] [Full Text] [Related]
8. Fabry disease.
Tarabuso AL
Skinmed; 2011; 9(3):173-7. PubMed ID: 21675497
[TBL] [Abstract][Full Text] [Related]
9. [Females with Fabry's disease - an interdisciplinary diagnostic and therapeutic challenge].
Weidemann F; Niemann M; Sommer C; Beer M; Breunig F; Wanner C
Med Klin (Munich); 2010 Sep; 105(9):627-34. PubMed ID: 20878300
[TBL] [Abstract][Full Text] [Related]
10. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
[TBL] [Abstract][Full Text] [Related]
11. The hearing status in 12 female and 15 male Japanese Fabry patients.
Sakurai Y; Kojima H; Shiwa M; Ohashi T; Eto Y; Moriyama H
Auris Nasus Larynx; 2009 Dec; 36(6):627-32. PubMed ID: 19261412
[TBL] [Abstract][Full Text] [Related]
12. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
[TBL] [Abstract][Full Text] [Related]
13. Fabry disease: an ultrastructural comparative study of skin in hemizygous and heterozygous patients.
Navarro C; Teijeira S; Dominguez C; Fernandez JM; Rivas E; Fachal C; Barrera S; Rodriguez C; Iranzo P
Acta Neuropathol; 2006 Feb; 111(2):178-85. PubMed ID: 16463201
[TBL] [Abstract][Full Text] [Related]
14. Natural history and treatment of renal involvement in Fabry disease.
Branton M; Schiffmann R; Kopp JB
J Am Soc Nephrol; 2002 Jun; 13 Suppl 2():S139-43. PubMed ID: 12068026
[No Abstract] [Full Text] [Related]
15. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.
Ortiz A; Oliveira JP; Wanner C; Brenner BM; Waldek S; Warnock DG
Nat Clin Pract Nephrol; 2008 Jun; 4(6):327-36. PubMed ID: 18431378
[TBL] [Abstract][Full Text] [Related]
16. [Cardiological follow-up in patients with Fabry disease].
Pieruzzi F; Pieroni M; Chimenti C; Frustaci A; Sarais C; Cecchi F;
G Ital Cardiol (Rome); 2010; 11(7-8):566-72. PubMed ID: 21033333
[TBL] [Abstract][Full Text] [Related]
17. Minimum requirement of donor cells to reduce the glycolipid storage following bone marrow transplantation in a murine model of Fabry disease.
Yokoi T; Kobayashi H; Shimada Y; Eto Y; Ishige N; Kitagawa T; Otsu M; Nakauchi H; Ida H; Ohashi T
J Gene Med; 2011 May; 13(5):262-8. PubMed ID: 21520359
[TBL] [Abstract][Full Text] [Related]
18. [Fabry disease--diagnostic guideline].
Constantin T; Rákóczi E; Ponyi A; Ambrus C; Kádár K; Vastagh I; Dajnoki A; Tóth B; Bokrétás G; Müller V; Katona M; Csikós M; Fiedler O; Széchey R; Varga E; Rudas G; Kertész A; Molnár S; Kárpáti S; Nagy V; Magyar P; Mahdi M; Németh K; Bereczki D; Garami M; Erdos M; Maródi L; Fekete G;
Orv Hetil; 2010 Feb; 151(7):243-9. PubMed ID: 20133243
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical diagnosis of Fabry nephropathy and localisation of globotriaosylceramide deposits in paraffin-embedded kidney tissue sections.
Valbuena C; Leitão D; Carneiro F; Oliveira JP
Virchows Arch; 2012 Feb; 460(2):211-21. PubMed ID: 22205110
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of patients with Fabry disease in Argentina].
AADELFA (Asociación Argentina de estudio de enfermedad de Fabry y otras enfermedades lisosomales)
Medicina (B Aires); 2010; 70(1):37-43. PubMed ID: 20228022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]